July 9th 2025
Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Burst CME Plus™ - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (CME Credit)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (COPE Credit)
View More
Retina Specialists: Join us in Long Beach
July 31, 2025 - August 2, 2025
Register Now!
SimulatED™: Pioneering Treat-and-Extend Therapy—The Impact of Early Application
View More
Rapid Reviews in Retina™: Emerging Updates from Summer 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
3rd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
September 6, 2025
Register Now!
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
View More
Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C/D
View More
EyeCon 2025
September 26-27, 2025
Register Now!
Optometrists: Earn COPE CE Credits in Portland or Virtually
October 16-17, 2025
Register Now!
Join us at The Ophthalmology Meeting in Orlando this October
October 18, 2025
Register Now!
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)
View More
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)
View More
Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Expert Perspectives on Technological Advances in Cataract Surgery
View More
Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy
View More
Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy
View More
(CME Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes
View More
(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention
View More
Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs
View More
(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes
View More
(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention
View More
(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention
View More
(COPE Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?
View More
(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?
View More
Glaucoma implants don't have staying power
March 1st 2007The Ahmed glaucoma valve (AGV) and the Molteno single plate implant (MSPI) may provide good early and intermediate-term control of intraocular pressure (IOP) in patients with neovascular glaucoma (NVG), but do not achieve the same success when implanted for long periods.
SLT comparable with glaucoma therapy
March 1st 2007Selective laser trabeculoplasty (SLT) is comparable to medical treatment as the initial therapy for open-angle glaucoma (OAG) or ocular hypertension, according to results of a study presented at the American Academy of Ophthalmology annual meeting, last year in Las Vegas.
Paediatric glaucoma: how should we be treating it?
September 1st 2006The management of paediatric glaucoma is primarily surgical. In the literature, goniotomy and trabeculotomy, despite success rates of only 40-90%, are still the initial surgical procedures of choice for most cases of primary congenital glaucoma. In the case of secondary glaucomas associated with conditions such as aphakia, aniridia, anterior segment dysgenesis and Sturge-Weber syndrome, the success rates of goniotomy or trabeculotomy are much lower.
IDK: the future of glaucoma surgery?
July 1st 2006The challenge of glaucoma surgery is not only to create a canal within the anterior chamber that acts as a pressure alleviator, it is to ensure that the canal is stable, will not close and, preferably, will alleviate intraocular pressure (IOP) to such an extent that medication is either no longer necessary or the frequency of dosing is minimized. This is the goal of every glaucoma surgeon and one that, unfortunately, is often not achieved, for a number of reasons.
Can we predict neovascular complications?
June 1st 2006Many ophthalmic disorders give rise to neovascularization of the iris and neovascular glaucoma. Almost all of these disorders are characterized by retinal hypoxia and retinal capillary nonperfusion, the same factors involved in the development of retinal neovascularization. One of the most common causes is central retinal vein occlusion (CRVO), which is a visually disabling disease that is second in prevalence only to diabetic retinopathy.
'Channel tracbeculectomy': scleral channel formation under the scleral flap
March 1st 2006Conventional trabeculectomy aims to control IOP by way of a guarded fistula between the anterior chamber and sub-conjunctival space via leakage past the scleral flap. The resulting bleb is often seen to form under the anterior conjunctiva, where Tenon's layer and the conjunctival tissue are thinnest, predisposing patients to bleb-related complications at or near the limbus. Complications include cystic bleb formation, blebitis, endophthalmitis, dellen ulcer and bleb dysaesthesia, the use of anti-metabolites often compounding these problems.
Assessing a novel trabeculectomy technique
March 1st 2006Since the late 1960s, trabeculectomy has been the operation of choice for improving aqueous outflow in glaucomatous eyes. Still today it remains the gold standard for glaucoma filtration surgery, with ophthalmologists accumulating a considerable amount of experience with the procedure, its advantages and its limitations.
Seeking the truth in the EGPS requires a critical review
October 1st 2005The surprising outcomes of the European Glaucoma Prevention Study (EGPS) can be accounted for by a number of explanations and should not be interpreted as meaning that lowering IOP has no benefit for glaucoma, said Harry A. Quigley, MD.